

82.6% of patients diagnosed with metastasis die from it.

THE PROBLEM

- 22 million new cancer cases each year
- 20% of people will develop some type of cancer in their lifetime
- 9 million cancer-related deaths per year
- 1 in 12 people will die from cancer

OUR SOLUTION

SS The power of one small molecule

AKOS

AKOS

÷

The first ever drug to halt metastasis A REVOLUTIONARY LEAP IN CANCER Zero METASTASIS, Zero DEATH

LIVER




mCAF Specific

MARKET

Global Oncology market valued at USD 305.07 Billion

In 2021, 70% of the development of new drugs came from external sources.



A small number of successful products represent a disproportionate share of the oncology market.

Global oncology prescription sales, ¹ 2019, \$ billion 143		Number of products ²	Product sales, 2019, \$ billion	
Blockbusters with sales of >\$5 billion	56	7	Keytruda (Merck) Revlimid (Celgene) Opdivo (Bristol Myers Squibb) Avastin (Roche) 7.1	11.1 11.1
Blockbusters with sales of \$1 billion- \$5 billion	56	28	Rituxan (Roche) 6.5 Herceptin (Roche) 6.1 Imbruvica (AbbVie) 5.7	
Nonblockbusters	31	219	Top ten oncology players produce 31 of 35 blockbusters All top ten players have at least one blockbuster, and eight have two or more	5

The perfect timing is now

OUR : TEAM





Javier Cerda Infante P.Universidad Católica

Co-FOUNDER **CFO & Business Develope**

FOUNDING TEAM



Benjamín Prieto P.Universidad Católica



Clinical-Oncolog ntific & Bus Advisory

Advisory

Scientific Advisory

Leading Re

Advisory



Advisor

M.D. Bruno Nervi PhD. Sergio Quezada Chief Scientific Officer at Achilles Therapeutics. P. Universidad Católica



at Metagenom

PhD Ralph Buttyan Co-Founder and Director Senior Scient Vancouver Prostate Center



searchers in Met Prevention and Life-Saving Innovations

PhD Nancy Lev Managing Partner at BostonLanding.us and Biohealth

INVESTMENT

Bridge Series: US 4.0 mil

SAFE



Valuation CAP: **US 30 MILLIONS**



Conversion milestone: Before 28 months or Series A



Discount rate: 30% Discount after 28 months

Key milestone / Drivers of value

Publication - Peer Validation e

ΞΞ IND - Technical Validation

Enhancing the PI Strategy

Contact:

Francisco Lozano, flozano@newgenesis.cl Raúl Vázquez, rvazquez@newgenesis.cl

